Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propofol + fentanyl + ketamine
- Development stage
- Phase 4
- Lead developer
- The University of Jordan
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Propofol + fentanyl + ketamine** is an intravenous procedural-sedation and analgesia regimen evaluated as an alternative to general anesthesia for endoscopic procedures and minor urological surgery. Propofol enhances inhibitory gamma-aminobutyric acid type A receptor signaling to produce rapid sedation and hypnosis, fentanyl is a potent mu-type opioid receptor agonist that provides analgesia, and ketamine is a noncompetitive N-methyl-D-aspartate receptor antagonist that provides dissociative anesthesia and analgesia. The combination is intended to achieve deep sedation with analgesia while potentially avoiding some requirements and risks of general anesthesia.
- Other names
- PFK
02
Targets
PFKFB3GABAA (Gamma-aminobutyric acid receptor)MOR (Mu opioid receptor)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on propofol + fentanyl + ketamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propofol + fentanyl + ketamine.